OncoMatch/Clinical Trials/NCT06834126
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
Is NCT06834126 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Consolidation Therapy and Papaverine for locally advanced rectal adenocarcinoma.
Treatment: Consolidation Therapy · Papaverine — This phase I trial studies the side effects and best dose of papaverine (PPV) when given together with radiation therapy (RT) and tests how well it works in treating patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). PPV is an enzyme inhibitor, and it may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. RT uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Giving PPV with RT may be safe, tolerable, and/or effective in treating patients with locally advanced rectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage II, III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Chemotherapy, biological therapy, immunotherapy within 14 days or five half-lives (whichever is shorter) prior to day 1 of protocol therapy
Cannot have received: biological therapy
Chemotherapy, biological therapy, immunotherapy within 14 days or five half-lives (whichever is shorter) prior to day 1 of protocol therapy
Cannot have received: immunotherapy
Chemotherapy, biological therapy, immunotherapy within 14 days or five half-lives (whichever is shorter) prior to day 1 of protocol therapy
Cannot have received: radiation therapy
Exception: prior pelvic irradiation resulting in overlapping fields
Prior pelvic irradiation resulting in overlapping fields
Lab requirements
Blood counts
ANC ≥ 1,500/mm^3; Platelets ≥ 100,000/mm^3; Hemoglobin ≥ 9g/dL (within 30 days of start)
Kidney function
Creatinine clearance of ≥ 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula (within 30 days of start)
Liver function
Total bilirubin ≤ 1.5 X ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN (within 30 days of start)
ANC ≥ 1,500/mm^3; Platelets ≥ 100,000/mm^3; Hemoglobin ≥ 9g/dL; Total bilirubin ≤ 1.5 X ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN; Creatinine clearance of ≥ 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify